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Abstract— Integrative in situ bio-sensing approaches became 
ominous to advance early stage detection of complex and 
heterogeneous disease like cancer, chronic lung, inflammation, 
coronary syndromes etc. Particularly in cancer, we can save 
million lives with existing therapeutic strategies if we can detect 
them at their very early stage. Unfortunately, cancer offers very 
rare distinctly identifiable cues during its onset to identify them 
and posing the technological challenges to spot them at their very 
early stage. We have developed an aptamer based integrated 
switchable rare event sensing platform using variable angle 
spectroscopic ellipsometry to spot in situ, readout and monitor 
rare events in real-time in complex heterogeneous cell 
population. The developed aptasensors is being tested with 
spotting prostate cancer cell PC3 in a blood mimicking 
population of human peripheral blood mononuclear cells 
(PBMC). The proof-of-concept data showed that the developed 
platform can detect in situ up to 10 target cells/ml with 109 
background cells. The integrated sensor is designed with 
switchable surface to safely capture and release the target cells 
for further clinical validation and analysis for advanced 
diagnosis. We envision this alternate integrated bio-sensors 
strategy will be an important step towards the development of 
label-free in situ biopsy technique for rare event detection and 
early stage detection of cancer. 
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I. INTRODUCTION 
Detection of early rare events in human can help to 
diagnose fatal diseases including cancer and can save 
thousands of lives [1]. However, only very few limited cues are 
available during early onset of such disease. On top of that 
these cues and biomarkers are not often uniquely distinct to be 
spotted clearly by sensing devices. The heterogeneous 
contributions to the similar biomarker due to several altered 
physiological condition makes it more difficult to detect [2]. 
Despite of these challenges, there are number of advanced 
biomedical methods have been developed those can precisely 
detect molecules even at the pico molar range[3]. 
Unfortunately, disease like cancer, inflammation etc. are 
not only heterogeneous but also dynamic in nature [4, 5]. They 
keep changing their expression molecule before being detected 
by our normal natural immune systems and leave us with this 
reality that there is no unique biomarker exist even at present 
time for the specific detection of cancer [6]. Therefore, 
proteomic, transcriptomic, lipidomic and metabolomics 
molecular detection systems and high throughput multiplex 
screening system are emerging as the validation tool for 
confirmatory diagnosis[7]. Despite these confirmatory support 
for clinical validation, none of them are easy accessible and 
suitable to design for an early stage spotting set up. Aptamer is 
rapidly emerging as a sensing molecule for their selective 
target recognition[8].  Furthermore, rare cell-selective aptamers 
can be achieved without targeting exact molecule on the cell 
surface. Systematic evolution of ligands by exponential 
enrichment (SELEX) offers the opportunity to select a whole 
cell and it could be possible that the derived aptamers could 
recognise several entity simultaneously on the target cell 
surface and that unique combination might be absent in similar 
cells[9-11]. There are number of aptamers are developing that 
could potentially bind to their unique targets. However, sensing 
through aptamer is not enough for their translational 
applications into the real clinical system until they are cross-
evaluated with the molecular diagnostics with standard 
operating protocols (SOP).  
In the present approach, we are proposing a novel in situ 
label free real time switchable bio-sensing platform that could 
potentially exploit to develop dynamic physiological event for 
detection of rare events such as early stage detection of cancer 
(in situ biopsies).  
II. EXPERIMENTAL 
A. Design of the sensor 
The present working hypothesis is based on the 
ellipsometry spectroscopy for label free sensing of the 
structural aspects of aptamer-cancer cell interactions[12]. The 
basic principle has been tested with cancer specific aptamer 
immobilized gold surface as described in Figure 1. In brief, 
preceding to immobilisation of wy-5a aptamer (5'- 
TGCCACTACAGCTGGTTCGGTTTGGTGACTTCGTTCTT
CGTTGTGGTGCTTAGTGGC-3') specific to PC3 cell (target 
cell), the gold coated silicon wafer surface was prudently 
washed with appropriate solvent sequentially (hexane-acetone-
ethanol-MilliQ). A uniform self-assembled monolayer of 3-
mercaptopropionic acid (MPA) was developed by incubating 
50mM MPA for 24h. The MPA-modified sensor surface was 
then washed several times with Milli-Q water and completely 
removed trace amount of unreacted MPA. The functionalised 
sensor surface were activated using 20mM EDC and 30mM 
sulfo-NHS solutions in MES for 2 h. We have co-grafted the 
amine functionalised 5′NH2-(CH2)6–Wy-5a aptamer and 
amine terminated Poly (N-isopropylacrylamide) (PNIPAAM)at 
the same time and the ratio was adjusted for optimal binding 
and release of PC3 cells. 
 
Figure1: Fabrication, basic schematic description and surface 
properties of the platform. 
B. Characterisation the sensor 
VASE: To optimise the sensor surface, we have used Variable 
angle Spectroscopic Ellipsometer (VASE from J.A. Woollam 
Co., Inc.) that can provide precise information from the 
immobilized sensor layer. The design described in Figure 2 has 
been used for in situ measurements using a variable angle 
spectroscopic ellipsometry (VASE) at an optimised angle of 
incidence of 68◦ in the spectral range 350–1050 nm to get an 
incident wavelength independent measure[13]. A specially 
designed cuvette (Figure 2c) have been used for the optical 
readout from the sensor surface[13] along with a magnetic 
stirrer and a flow system for simulating the blood flow. The 
sensor was first incubated in PBS at pH 7.4 and performed the 
spectral measurements without target cells. Followed by target 
cells have been added and the corresponding spectral changes 
monitored. A negative control has been kept for each 
individual set of experiment. 
 
Figure 2: Basic set up (a) and principal components (b-c) of 
the VASE and real time monitoring (d-e) 
C.  Electrochemical end electron microscopy study 
All voltammetry measurements were carried out with an Ivium 
Stat.XR electrochemical analyser (Eindoven, Netherlands). A 
three-electrode cell with gold plate working electrode, having 
1.00 cm2 surface area, platinum wire auxiliary and Ag/AgCl (3 
M KCl) reference electrodes were used in the voltammetry 
measurements[14]. Temperature controlled SEM was 
performed using an LEO 155 Gemini (Zeiss, OR, USA) by 
attaching a H1002 hot-stage module for heating and water 
cooling apparatus as described in Figure 3.  
 
Figure 3: Set-up for temperature-controlled SEM device, 
stage holder (a-c) and external temperature controller (d). 
III. RESULTS AND DISCUSSION 
In this present report we have developed an aptamer-based 
platform to detect rare events in real time. Wy-5a is 
immobilised along with temperature responsive polymer 
PNIPAAM suitable for the biosystem [15-16]. 
 
Figure4: In situ real time target cell sensing 
The surface of the sensor is being characterised and optimised 
by VASE and found regions that could be exploited for sensing 
events independently irrespective of the wavelength. To 
validate the hypothesis a proof-of-concept set up has been 
developed where we have used a specifically designed cuvette 
to measure the response with real-time. It has been found that 
sensor is not responding when the target cell is absent. PBMC 
have been used to mimic the similar blood mimicking 
condition as off-target in Figure 4. However, we have found a 
consistent change in delta and psi value in presence of the 
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specific target cells (PC3) with respect to time at 37°C.  
Figure 5: Switchable sensor surface. The electron microscopic 
structural change induced by the temperature (a to b) and 
reflected by their electrochemical (c) and contact angle 
measurement (d) 
The polarization change is represented as an amplitude ratio, 
Ψ, and the phase difference, Δ as described in Figure 4. This 
confirms the capture of the target cells on the sensor surface as 
reconfirmed by Laser Scanning Confocal Microscopy (LSCM) 
as shown in Figure 6 (left panel). We have found that in a 
blood mimicking condition with similar cell population and 
flow, we can sense in situ up to 10 target cells/ml of blood 
where the background cell count in 109.  
Figure 6: LSCM images of real captured and release cells 
from the sensor after detection for further advanced diagnosis 
The developed sensor surface has controllable thermo-
switchable properties as showed in Figure 5. After capturing 
the target cells, upon reducing the temperature to 25°C () can 
allow to remove the cells from the sensor surface as illustrated 
in Figure 7 and showed directly in LSCM release data in 
Figure 6. The safe removal of 95% live target cells was further 
reconfirmed by flow cytometry (Figure 7b) with dual probe 
Po-pro and 7-AAD. The idea is to recover those captured cells 
for further advanced diagnosis such as tumour staging etc.  
 
Figure 7: Towards in situ biopsy for detection and capture of 
cancer cell in its early stage of asymptomatic patients before 
the onset of metastasis. 
IV CONCLUSION 
An integrated label-free aptasensor reported that is equipped 
with switchable architecture enable us to detect, capture and 
release the target cells through a non-enzymatic and mechano-
thermal procedure with biocompatible temperature range 20 -
37°C for further advanced clinical analysis. 
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